Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symptom Assessment in GERD Patients Receiving H. Pylori Eradication
NCT02934152Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Oct 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rabeprazole, amoxicillin and clarithromycin in Helicobacter pylori infection and gastroesophageal reflux disease (GERD) (3 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Incidence of acid rebound. Status: unknown.
02
Drugs
rabeprazoleamoxicillinclarithromycin
03
Conditions
Helicobacter pylori infectiongastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02934152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934152.